1. Academic Validation
  2. Pre-Clinical Evaluation of the Antiviral Activity of Epigalocatechin-3-Gallate, a Component of Green Tea, against Influenza A(H1N1)pdm Viruses

Pre-Clinical Evaluation of the Antiviral Activity of Epigalocatechin-3-Gallate, a Component of Green Tea, against Influenza A(H1N1)pdm Viruses

  • Viruses. 2023 Dec 16;15(12):2447. doi: 10.3390/v15122447.
Harry Stannard 1 Paulina Koszalka 1 Nikita Deshpande 1 Yves Desjardins 2 Mariana Baz 1 3
Affiliations

Affiliations

  • 1 WHO Collaborating Centre for Reference and Research on Influenza, at the Peter Doherty Institute for Infection and Immunity, Melbourne, VIC 3000, Australia.
  • 2 Institute of Nutrition and Functional Foods, Centre Nutrition, Santé et Societé (NUTRISS) Center, Faculté de Sciences de L'agriculture et de L'alimentation (FSAA), Université Laval, Quebec City, QC G1V 4L3, Canada.
  • 3 Department of Microbiology and Immunology, at the Peter Doherty Institute for Infection and Immunity, The University of Melbourne, Melbourne, VIC 3000, Australia.
Abstract

Influenza Antiviral drugs are important tools in our fight against both annual influenza epidemics and pandemics. Polyphenols are a group of compounds found in Plants, some of which have demonstrated promising Antiviral activity. Previous in vitro and mouse studies have outlined the anti-influenza virus effectiveness of the polyphenol epigallocatechin-3-gallate (EGCG); however, no study has utilised the ferret model, which is considered the gold-standard for influenza Antiviral studies. This study aimed to explore the Antiviral efficacy of EGCG in vitro and in ferrets. We first performed studies in Madin-Darby Canine Kidney (MDCK) and human lung carcinoma (Calu-3) cells, which demonstrated Antiviral activity. In MDCK cells, we observed a selective index (SI, CC50/IC50) of 77 (290 µM/3.8 µM) and 96 (290 µM/3.0 µM) against A/California/07/2009 and A/Victoria/2570/2019 (H1N1)pdm09 Influenza Virus, respectively. Calu-3 cells demonstrated a SI of 16 (420 µM/26 µM) and 18 (420 µM/24 µM). Ferrets infected with A/California/07/2009 Influenza Virus and treated with EGCG (500 mg/kg/day for 4 days) had no change in respiratory tissue viral titres, in contrast to oseltamivir treatment, which significantly reduced viral load in the lungs of treated Animals. Therefore, we demonstrated that although EGCG showed Antiviral activity in vitro against influenza viruses, the drug failed to impair viral replication in the respiratory tract of ferrets.

Keywords

Epigalocatechin-3-gallate; combinational therapy; ferret model; influenza antiviral treatment; influenza viruses; oseltamivir; polyphenol.

Figures
Products